Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant Charcot-Marie-Tooth disease type 2J (CMT2J) is a form of axonal Charcot-Marie-Tooth disease, a peripheral sensorimotor neuropathy, characterized by a relatively late onset, pupillary abnormalities and deafness, in most patients, associated with distal weakness and muscle atrophy.
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 2:54 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease type 2J
Features include always present findings: Recurrent coughing spasms. 15 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 3 | Hyporeflexia, Difficulty swallowing (dysphagia), Steppage gait |
Muscles | 2 | Distal muscle weakness, Foot dorsiflexor weakness |
Ears | 2 | Progressive sensorineural hearing impairment, Inner ear hearing loss (sensorineural hearing impairment) |
Digestive system | 1 | Difficulty swallowing (dysphagia) |
Arms and legs | 1 | Foot dorsiflexor weakness |
Age of onset: adulthood.
MPZ encodes myelin protein zero (248 aa). Is an adhesion molecule necessary for normal myelination in the peripheral nervous system. It mediates adhesion between adjacent myelin wraps and ultimately drives myelin compaction Highest expression in Nerve Tibial (5,301 TPM) and Colon Sigmoid (33.9 TPM).
Charcot-Marie-Tooth disease type 2J is associated with mutations in the MPZ gene on chromosome 1.
The MPZ protein participates in MPZ gene:EGR2:SOX10:SMARCA4, MPZ gene expression, and EGR2, SOX10 and SMARCA4 bind the MPZ gene pathways.
MPZ is classified as a druggable target (Druggable Genome category) with score 0.0.
Genetic testing for MPZ is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature.
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
3 publications have been identified in PubMed for Charcot-Marie-Tooth disease type 2J. Research spans Basic Science / Preclinical (67%) and Epidemiology / Natural History (33%).
Liu M (2026). [PMID: 41391004](https://pubmed.ncbi.nlm.nih.gov/41391004/). *Aging cell*. [Basic Science / Preclinical]
Yalcouyé A (2025). [PMID: 40320863](https://pubmed.ncbi.nlm.nih.gov/40320863/). *Brain and behavior*. [Epidemiology / Natural History]
Maino A (2025). [PMID: 41363019](https://pubmed.ncbi.nlm.nih.gov/41363019/). *Journal of the peripheral nervous system : JPNS*. [Basic Science / Preclinical]